STAT

Nerd’s notes: How we did the ClinicalTrials.gov data analysis

I have a dream that one day all public information and all software will be free, transparent, and open source, and all people will have the skills to benefit from it. We are not living in my dream world yet. But here at STAT, we’re trying to do our part to open up a little more data stored in government databases.

Our first major project after we launched was a deep data-intensive dive into clinical trials compliance. In December 2015, we published “Failure to Report,” an investigation of the reporting of human study results to ClinicalTrials.gov by government, academic, and industry scientists. We found flagrant violations of federal law and non-existent enforcement.

We didn’t just publish and hope for the best. We went back this year to check whether research organizations were doing a better job posting results. That appears to.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks